References
- Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Fontana: Gold; 2019 [cited 2019 May 23]. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf.
- Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35:71–86. doi:10.1016/j.ccm.2013.10.004.
- Hansen JE, Sun X-G, Wasserman K. Spirometric Criteria for Airway Obstruction. CHEST. 2007;131:349–355. doi:10.1378/chest.06-1349.
- Medbø A, Melbye H. Lung function testing in the elderly-can we still use FEV1/FVC<70% as a criterion of COPD? Respir Med. 2007;101:1097–1105. doi:10.1016/j.rmed.2006.11.019.
- Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, Jensen RL, Falaschetti E, Schouten JP, Hankinson JL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63:1046–1051. doi:10.1136/thx.2008.098483.
- Boppana LKT, Sakhamuri S, Seemungal T. Spirometric instability - another hurdle in achieving real-world COPD diagnostic criteria? COPD. 2018; 15:557–558. doi:10.1080/15412555.2018.1534947.
- Ramirez-Venegas A, Sansores RH, Quintana-Carrillo RH, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. Am J Respir Crit Care Med. 2014;190:996–1002. doi:10.1164/rccm.201404-0720OC.
- Torres-Duque CA, Garcia-Rodriguez MC, Gonzalez GM. Is chronic obstructive pulmonary disease caused by wood smoke a different phenotype or a different entity?. Arch Bronconeumol. 2016;52:425–431.
- Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;10:CD010115.
- Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234. doi:10.1056/NEJMoa1516385.
- Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117–126. doi:10.1016/S2213-2600(18)30006-7.